Biocrates Life Sciences AG, corporate

Biocrates Life Sciences AG,

12.09.2019 - 11:32:28

Repositioning of Biocrates: Management change and new round of financing

Repositioning of Biocrates: Management change and new round of financing

Innsbruck, Austria - September 12, 2019 - Biocrates Life Sciences AG, one of the world's leading biotech companies in the field of metabolomics, is strategically realigning. Dr. Nicolas Schauer is appointed as the new Co-CEO|CSO and Moritz Seuster as the new Co-CEO|CFO. Dr. Wulf Fischer-Knuppertz is resigning from the Executive Board and will continue to serve as a consultant. Biocrates recently received funding from MIG Fonds and GAF, as well as a renowned Austria-based family office, to strengthen its kit business and tap into new business areas.

"The reframing of Biocrates is essential in order to expand the attractive kit and service portfolio and to sustainably develop it for the future. At the same time, we want to create new diagnostic possibilities for our customers in the metabolomics market in order to give them a deeper insight into human health and wellbeing," stresses Dr. Nicolas Schauer, Co-CEO|CSO of Biocrates.

Dr. Nicolas Schauer has more than 15 years of experience in the global metabolomics market. Prior to joining Biocrates as Co-CEO|CSO, he successfully sold his own metabolite profiling company two years ago. The new management team will transform Biocrates from a single supplier of metabolomics kits to a broad player within the diagnostics market. "The board is convinced that Dr. Nicolas Schauer and Moritz Seuster in their Co-CEO roles are a perfect team for reframing Biocrates," says Dr. Matthias Kromayer, Member of the Biocrates Supervisory Board and Member of the Management Board at MIG.

Over the course of finance and management changes, the number of shareholders was downsized. Long-established shareholders such as MIG Fonds and GAF participated in the new financing round to support Biocrates' sustainable growth and now have a significant majority in the company. Moritz Seuster, the former COO|CFO, has been driving the reorganization of the company since the beginning of the year.

"The new round of financing and the trust of our long-term investors illustrate the tremendous potential of Biocrates' technology portfolio for the healthcare and biotech industries. With the closure of the Berlin site, Biocrates Life Sciences AG can focus on its core business and initiate important developments in the R&D area," commented Moritz Seuster, Co-CEO|CFO of Biocrates.

About Biocrates Life Sciences AG Biocrates is one of the world's leading companies for targeted metabolite analysis products and services. Based in Innsbruck and with a subsidiary in the US, the company provides user-friendly and ready-to-measure kits for quantitative metabolite analysis. As a result, research laboratories have access to efficient metabolite analysis. Possible application areas include human and animal health, nutrition, feed and microbiome.

For further information, please contact: Biocrates Life Sciences AG Dr. Nicolas Schauer T +43 512 579 823 E MC Services AG Dr. Claudia Riedl, Senior Advisor T +49 89 210228-0 E

12.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at

872691  12.09.2019